JP2012229267A - 肝機能改善剤 - Google Patents
肝機能改善剤 Download PDFInfo
- Publication number
- JP2012229267A JP2012229267A JP2012179313A JP2012179313A JP2012229267A JP 2012229267 A JP2012229267 A JP 2012229267A JP 2012179313 A JP2012179313 A JP 2012179313A JP 2012179313 A JP2012179313 A JP 2012179313A JP 2012229267 A JP2012229267 A JP 2012229267A
- Authority
- JP
- Japan
- Prior art keywords
- value
- liver function
- serum
- glucosyl hesperidin
- hesperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003908 liver function Effects 0.000 title claims abstract description 59
- 230000000246 remedial effect Effects 0.000 title abstract 2
- IMMBLRJLSYJQIZ-UNQGIHKMSA-N (2S)-7-[3,4-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one Chemical compound COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(OC3OC(COC4OC(C)C(O)C(O)C4O)C(OC4OC(CO)C(O)C(O)C4O)C(O)C3O)cc2O1 IMMBLRJLSYJQIZ-UNQGIHKMSA-N 0.000 claims abstract description 70
- 238000002360 preparation method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 244000269722 Thea sinensis Species 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- -1 cyclic tetrasaccharide Chemical class 0.000 claims description 6
- 235000009569 green tea Nutrition 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000013616 tea Nutrition 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 239000002211 L-ascorbic acid Substances 0.000 claims description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 229940094952 green tea extract Drugs 0.000 claims description 3
- 235000020688 green tea extract Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000007865 diluting Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 8
- 241000124008 Mammalia Species 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 description 51
- 238000012360 testing method Methods 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 25
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 20
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 20
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 20
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 20
- 229940025878 hesperidin Drugs 0.000 description 20
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 20
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 18
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 12
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 230000005976 liver dysfunction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 102000051366 Glycosyltransferases Human genes 0.000 description 3
- 108700023372 Glycosyltransferases Proteins 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019670 Hepatic function abnormal Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229940108690 glucosyl hesperidin Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QSWJLWOBQYWQMW-NVUYQKBASA-N CC([C@@H](C(C1O)O)O)O[C@H]1OCC([C@@H](COC[C@H](C(C1O)O)OC(CO)[C@H]1O)C(C1O)O)O[C@H]1Oc1cc(O)c(C(CC(c(cc2)cc(O)c2OC)O2)=O)c2c1 Chemical compound CC([C@@H](C(C1O)O)O)O[C@H]1OCC([C@@H](COC[C@H](C(C1O)O)OC(CO)[C@H]1O)C(C1O)O)O[C@H]1Oc1cc(O)c(C(CC(c(cc2)cc(O)c2OC)O2)=O)c2c1 QSWJLWOBQYWQMW-NVUYQKBASA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- YPIQVCUJEKAZCP-UHFFFAOYSA-N Malotilate Chemical compound CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 YPIQVCUJEKAZCP-UHFFFAOYSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- MYGVPKMVGSXPCQ-JEDNCBNOSA-N Methylmethionine sulfonium salt Chemical compound [Cl-].C[S+](C)CC[C@H](N)C(O)=O MYGVPKMVGSXPCQ-JEDNCBNOSA-N 0.000 description 1
- CKMNPXWFAZLBNK-QOFYEYOWSA-N OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O Chemical compound OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O CKMNPXWFAZLBNK-QOFYEYOWSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N baicalein Chemical compound C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000008581 daisaikoto Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229950000470 malotilate Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000021542 oral nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000008485 shosaiko-to Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 101150067597 treh gene Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Tea And Coffee (AREA)
- Saccharide Compounds (AREA)
Abstract
【解決手段】 有効成分としてα−グルコシルヘスペリジンを含んでなる肝機能改善剤とその用途を提供することによって上記課題を解決する。
【選択図】なし
Description
本発明で使用する藍草は、その起源や栽培方法に特に制限はなく、天然に自生する藍草でも、栽培されているものでもよく、これらを常法により育種して得られる変異株などでもよく、また、藍草を、組織培養、カルス培養、細胞培養などして得られる培養物であってもよい。植物体を抽出の原料として用いる場合、その植物体の一部又は全部を用いることができる。また、これらの原料は新鮮な、すなわち、水分を含む状態であっても、凍結品であっても、或いは、乾燥させた状態であっても、これらの混合物であってもよい。
α−グルコシルヘスペリジンの摂取が肝機能に与える影響を調べる目的で、ハムスターを用いて動物試験を実施した。
実験1の結果を踏まえ、α−グルコシルヘスペリジンの長期摂取がヒトの肝機能に与える影響を調べる目的で、ボランティア試験を実施した。
まず、実験2により得た試験結果を、肝機能値に着目して解析した。被験者25名をその試験前の肝機能値、すなわち、血清GOT値、GPT値又はγ−GT値に基づき2つの群、すなわち、高値を示す群(High)と正常値を示す群(Normal)とに分類した。表2に肝機能値による被験者の分類、分類に用いたGOT、GPT及びγ−GTの各値、及びそれぞれの群の投与開始4週間前と投与開始時(投与0週)のデータを合わせたものの平均値及び標準偏差を投与開始前値として示した。
実験2の試験結果を用い、被験者の血清TG濃度の見地から異なる解析を試みた。被験者を、試験前の血清TG濃度により3つの群、すなわち、高TG群(以下、「High−TG群」と略称する。血清TG濃度150mg/dL超、8名)、正常TG群(以下、「Normal−TG群」と略称する。血清TG濃度110mg/dL未満、6名)、及びこれらの中間群(以下、「Border−TG群」と略称する。血清TG濃度110乃至150mg/dL、11名)に分類し、それぞれの群に属する被験者のデータの平均値と標準偏差を求めることにより血清TG濃度による分類別に解析した。α−グルコシルヘスペリジン錠剤投与試験における各群の被験者の血清TG濃度、GOT値、GPT値及びγ−GT値の変化をそれぞれ、表6、表7、表8及び表9に、また、それぞれの表における投与開始前値を基準として値の変化を図示したものを図4、図5、図6及び図7に示す。
L−アスコルビン酸10質量部、α−グルコシルヘスペリジン粉末(商品名『αGヘスペリジンPS』、株式会社林原商事販売)19質量部、マルトース(登録商標『サンマルト』、株式会社林原商事販売)70質量部、及びショ糖ステアリン酸エステル1質量部をそれぞれ均一に混合した後、常法により打錠してα−グルコシルヘスペリジンを含有する錠剤を得た。摂取し易く、溶解性に優れビタミンCの補給もできる本品は、肝機能改善剤として有用である。
市販のα−マルトシルトレハロース含有シラップ(登録商標『ハローデックス』、株式会社林原商事販売)150質量部を減圧下で加熱して水分含量15質量%まで濃縮し、常法に従ってゼラチン13質量部を水18質量部に溶解したものとα−グルコシルヘスペリジン粉末(商品名『αGヘスペリジンPA』、株式会社林原商事販売)2質量部、クエン酸2質量部、並びに適量の着色料及び着香剤を均一に混合した後、成型し、包装してα−グルコシルヘスペリジンを含有するグミキャンディーを得た。本品は、テキスチャー、風味ともに良好であり、肝機能の改善・維持に用いる健康食品として有用である。
ガムベース3質量部を柔らかくなるまで加熱融解し、含水結晶トレハロース(登録商標『トレハ』、株式会社林原商事販売)6質量部及びα−グルコシルヘスペリジン粉末(商品名『αGヘスペリジンPA』、株式会社林原商事販売)を1質量部加え、さらに、ビタミンEを0.1質量部と適量の着色料、着香料をそれぞれ混合した後、常法により練り合わせ、成型し、包装してα−グルコシルヘスペリジンを含有するチューインガムを得た。本品は、テキスチャー、風味ともに良好であり、肝機能の改善・維持に用いる健康食品として有用である。
異性化糖40質量部、マルチトール(商品名『粉末マビット』、株式会社林原商事販売)2質量部、米酢10質量部、リンゴ酢6質量部、クエン酸2質量部、リンゴ酸2質量部、濃縮リンゴ果汁2質量部、α−グルコシルヘスペリジン粉末(商品名『αGヘスペリジンPS』、株式会社林原商事販売)2質量部を混合・溶解して飲料を調製した。本品は、風味、呈味ともに良好であり、肝機能を改善・維持するための健康補助飲料として有用である。
ブレンドした緑茶50質量部を、65℃のイオン交換水1500質量部で5分間抽出し、続いて濾紙で濾過することにより茶葉を除去して、1320質量部の緑茶抽出液を得た。この緑茶抽出液を飲用濃度となるようイオン交換水で5倍希釈し、L−アスコルビン酸を300ppmとなるように添加した後、炭酸水素ナトリウムでpH6.0に調整し、調合液を得た。この調合液に、α−グルコシルヘスペリジン(商品名『αGヘスペリジンPA』、株式会社林原商事販売)及び国際公開WO 02/10361号明細書に開示された環状四糖5含水結晶を、各々の濃度が、無水物換算で、0.2質量%及び1.5質量%となるように添加した。この調合液をガラス容器に250gずつ充填・密封し、レトルト殺菌(121℃、7分間)を行って緑茶飲料とした。本品は、肝機能の改善・維持に用いる健康補助飲料として有用である。また、本品は、α−グルコシルヘスペリジン及び環状四糖が、血中や他の組織のコレステロールや中性脂肪を低減する作用を有していることから、脂質低減のために用いられる旨の表示を付して、高脂血症や肥満などの生活習慣病の予防及び治療の目的にも有利に利用できる。
無水結晶マルトース(登録商標『ファイントース』、株式会社林原商事販売)30質量部、グルタミン酸ナトリウム3質量部、グリシン2質量部、食塩2質量部、クエン酸2質量部、炭酸マグネシウム0.3質量部、乳酸カルシウム1質量部、α−グルコシルヘスペリジン粉末(商品名『αGヘスペリジンPA』、株式会社林原商事販売)4質量部、チアミン0.02質量部及びリボフラビン0.02質量部からなる配合物を調製した。この配合物を30gずつラミネートアルミ袋に小分けし、ヒートシールして経管経口栄養剤を調製した。本品は、一袋約250乃至500mlの滅菌水に溶解し経管又は経口的に栄養剤として、また、肝機能を改善・維持するための液剤として有利に利用できる。
●:肝機能値高値群(High)
○:肝機能値正常値群(Normal)
図4乃至7において
●:High−TG群
△:Border−TG群
○:Normal−TG群
図1乃至7を通じて
*:投与開始前値に対して危険率5%未満で有意差あり。
**:投与開始前値に対して危険率1%未満で有意差あり。
Claims (3)
- 緑茶を水抽出する工程と、ろ過により茶葉を除去する工程と、得られた緑茶抽出液を適宜希釈し、L−アスコルビン酸を含有させた後にpHを調整する工程と、それによって得られた調合液にα−グルコシルヘスペリジンとともに環状四糖を含有させる工程とを含むことを特徴とする緑茶飲料の製造方法。
- 緑茶飲料が、高脂血症の抑制及び/又は肝機能改善のための健康補助飲料である、請求項1記載の緑茶飲料の製造方法。
- 環状四糖が5含水結晶である請求項1又は2記載の緑茶飲料の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012179313A JP5487260B2 (ja) | 2004-12-24 | 2012-08-13 | 肝機能改善剤 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004373663 | 2004-12-24 | ||
JP2004373663 | 2004-12-24 | ||
JP2005121587 | 2005-04-19 | ||
JP2005121587 | 2005-04-19 | ||
JP2012179313A JP5487260B2 (ja) | 2004-12-24 | 2012-08-13 | 肝機能改善剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006548730A Division JP5694628B2 (ja) | 2004-12-24 | 2005-11-21 | 肝機能改善剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013053513A Division JP5705898B2 (ja) | 2004-12-24 | 2013-03-15 | 肝機能改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012229267A true JP2012229267A (ja) | 2012-11-22 |
JP5487260B2 JP5487260B2 (ja) | 2014-05-07 |
Family
ID=36601530
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006548730A Active JP5694628B2 (ja) | 2004-12-24 | 2005-11-21 | 肝機能改善剤 |
JP2012179313A Active JP5487260B2 (ja) | 2004-12-24 | 2012-08-13 | 肝機能改善剤 |
JP2013053513A Active JP5705898B2 (ja) | 2004-12-24 | 2013-03-15 | 肝機能改善剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006548730A Active JP5694628B2 (ja) | 2004-12-24 | 2005-11-21 | 肝機能改善剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013053513A Active JP5705898B2 (ja) | 2004-12-24 | 2013-03-15 | 肝機能改善剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20080221045A1 (ja) |
EP (1) | EP1837026A4 (ja) |
JP (3) | JP5694628B2 (ja) |
KR (2) | KR20070095338A (ja) |
WO (1) | WO2006067925A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006067925A1 (ja) * | 2004-12-24 | 2006-06-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 肝機能改善剤 |
JP5197560B2 (ja) * | 2009-12-21 | 2013-05-15 | 株式会社 伊藤園 | ヘスペリジン含有飲料 |
WO2011155505A1 (ja) | 2010-06-09 | 2011-12-15 | 花王株式会社 | ポリフェノール組成物の製造方法 |
KR101268325B1 (ko) | 2010-12-30 | 2013-05-31 | 한국식품연구원 | 플라보노이드를 포함하는 알코올성 간질환 예방용 조성물 |
JP6437183B2 (ja) * | 2012-11-30 | 2018-12-12 | 上野製薬株式会社 | 肝機能改善剤 |
KR101746099B1 (ko) | 2015-05-29 | 2017-06-13 | 주식회사 금림바이오켐 | 간기능 개선용 조성물 및 이를 이용한 간기능 개선제의 제조방법 |
US20210236594A1 (en) * | 2018-04-24 | 2021-08-05 | Genome Protection, Inc. | Methods for improving frailty and aging |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010361A1 (fr) * | 2000-08-01 | 2002-02-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Synthase d'$g(a)-isomaltosylglucosaccharide, procede de preparation et utilisation associes |
WO2002038146A1 (fr) * | 2000-11-07 | 2002-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Immunomodulateur mucosal et son utilisation |
JP2003160495A (ja) * | 2001-11-20 | 2003-06-03 | Hayashibara Biochem Lab Inc | 活性酸素消去能低減抑制剤 |
JP2004194590A (ja) * | 2002-12-19 | 2004-07-15 | Ito En Ltd | リラックス効果のある飲食物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3060227B2 (ja) | 1989-06-03 | 2000-07-10 | 株式会社林原生物化学研究所 | α―グリコシル ヘスペリジンとその製造方法並びに用途 |
JP3833775B2 (ja) * | 1996-06-26 | 2006-10-18 | 株式会社林原生物化学研究所 | 酵素処理ヘスペリジンおよびその製造方法ならびに酵素処理ヘスペリジンの使用方法 |
EP1063988A1 (en) | 1997-10-28 | 2001-01-03 | Korea Institute Of Science And Technology | Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor ofmacrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
JP3549436B2 (ja) * | 1999-04-08 | 2004-08-04 | 株式会社林原生物化学研究所 | α−グリコシルヘスペリジンとその製造方法並びに用途 |
WO2006067925A1 (ja) * | 2004-12-24 | 2006-06-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 肝機能改善剤 |
-
2005
- 2005-11-21 WO PCT/JP2005/021332 patent/WO2006067925A1/ja active Application Filing
- 2005-11-21 JP JP2006548730A patent/JP5694628B2/ja active Active
- 2005-11-21 KR KR1020077016368A patent/KR20070095338A/ko active Search and Examination
- 2005-11-21 US US11/722,735 patent/US20080221045A1/en not_active Abandoned
- 2005-11-21 KR KR1020137010607A patent/KR101356330B1/ko active IP Right Grant
- 2005-11-21 EP EP05809590A patent/EP1837026A4/en not_active Withdrawn
-
2010
- 2010-04-27 US US12/768,625 patent/US20100210589A1/en not_active Abandoned
-
2012
- 2012-08-13 JP JP2012179313A patent/JP5487260B2/ja active Active
-
2013
- 2013-03-15 JP JP2013053513A patent/JP5705898B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010361A1 (fr) * | 2000-08-01 | 2002-02-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Synthase d'$g(a)-isomaltosylglucosaccharide, procede de preparation et utilisation associes |
WO2002038146A1 (fr) * | 2000-11-07 | 2002-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Immunomodulateur mucosal et son utilisation |
JP2003160495A (ja) * | 2001-11-20 | 2003-06-03 | Hayashibara Biochem Lab Inc | 活性酸素消去能低減抑制剤 |
JP2004194590A (ja) * | 2002-12-19 | 2004-07-15 | Ito En Ltd | リラックス効果のある飲食物 |
Also Published As
Publication number | Publication date |
---|---|
KR101356330B1 (ko) | 2014-01-27 |
JP5694628B2 (ja) | 2015-04-01 |
EP1837026A1 (en) | 2007-09-26 |
US20100210589A1 (en) | 2010-08-19 |
KR20130050392A (ko) | 2013-05-15 |
JPWO2006067925A1 (ja) | 2008-06-12 |
WO2006067925A1 (ja) | 2006-06-29 |
JP5705898B2 (ja) | 2015-04-22 |
EP1837026A4 (en) | 2010-03-24 |
JP5487260B2 (ja) | 2014-05-07 |
US20080221045A1 (en) | 2008-09-11 |
KR20070095338A (ko) | 2007-09-28 |
JP2013116918A (ja) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5705898B2 (ja) | 肝機能改善剤 | |
JP6335508B2 (ja) | 成長ホルモン分泌促進剤 | |
KR20230152614A (ko) | 인지 기능 속도 개선용 조성물 | |
JPWO2005074961A1 (ja) | 体脂肪調整剤 | |
TWI225789B (en) | Compositions inhibiting muscle atrophy | |
KR20220001315A (ko) | 백리향 추출물을 포함하는 숙취의 예방 또는 치료용 조성물 | |
JP2010111646A (ja) | 潰瘍性大腸炎治療剤 | |
CN112472733B (zh) | 一种促进钙口服吸收的葛花提取物 | |
JP2021500382A (ja) | 非アルコール性脂肪肝疾患の予防または改善用組成物 | |
JPWO2006006267A1 (ja) | 抗ストレス剤 | |
US20090318552A1 (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof | |
JP4464082B2 (ja) | ヨモギを有効成分として含有する筋肉細胞糖輸送促進組成物 | |
KR100540498B1 (ko) | 아스타잔틴 및 아스파라긴산을 함유하는 숙취해소제 | |
JP2009209088A (ja) | アスペルロシドまたはその類縁体を含む筋肉増強剤 | |
EP3578587B1 (en) | Novel compound hexadecaphlorethol isolated from ishige okamurae and use thereof | |
JP4228371B2 (ja) | カロチノイド含有馬鈴薯に含まれるアポトーシス誘導物質、馬鈴薯由来の胃癌細胞増殖抑制作用又は胃癌発生阻害作用を有する抗癌剤 | |
KR100591791B1 (ko) | 비만 억제용 음료 | |
CN113397076A (zh) | 一种中药饮品组合物及其制备方法 | |
KR101490800B1 (ko) | 붉은덕다리버섯의 물 추출물을 포함하는 고지혈증 치료 또는 예방용 조성물 | |
KR20190015423A (ko) | 아위느타리버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
CN113100443A (zh) | 一种缓解痛风组合物、软胶囊及其制备方法 | |
JPH1160490A (ja) | 肝機能調節剤 | |
KR20040087808A (ko) | 아스타잔틴 및 아스파라긴산을 함유하는 숙취해소제 | |
KR20170087064A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
KR20040087809A (ko) | 아스타잔틴, 아스파라긴산 및 갈화 추출액을 함유하는숙취해소제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140224 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5487260 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |